Flamel Technologies S.A.

Flamel Technologies is a drug delivery company with expertise in polymer chemistry.

The company was founded in 1990.

In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq.

The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns a 50,000-square foot cGMP pharmaceutical production facility located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules).

Flamel’s drug delivery platforms, Medusa® for therapeutic proteins and peptides, and Micropump® for small molecules, have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs.

The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.

Flamel has partnership agreements with major pharmaceutical companies.

The Company is actively seeking partnership agreements for the development and commercialization of products currently in its pipeline as well as for new products using Flamel’s proprietary delivery systems.